VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue guidance for FY2027, and announced that it has received a $5 million payment from Eli Lilly.

VivoSim further announced that it anticipates significant revenue growth in Fiscal Year 2027 given its progress in marketing contract research services using NAMs models to pharmaceutical companies. The company anticipates over 500% revenue growth in the fiscal year, due to customer response to the predictive power of its NAMs models, which are building traction with a wide set of customers.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.